lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer

Wang, Zehua; Yang, Bo; Zhang, Min; Guo, Weiwei; Wu, Zhiyuan; Wang, Yue; Jia, Lin; Li, Song; Xie, Wen; Yang, Da

doi:10.1016/j.ccell.2018.03.006

Cited by 375 publications

(340 citation statements)

References 70 publications

Supporting

Mentioning

332

Contrasting

Unclassified

Order By: Relevance

“…Although great advances in early detection and treatment strategy lead to the steadily declined mortality, recurrence, and metastasis still occurred frequently and remained the major reasons for cancer deaths in patients with BC. Currently, a wide array of noncoding RNAs including microRNAs (miRNAs; Zare, Bastami, Solali, & Alivand, ), long noncoding RNAs (Wang et al, ) and circular RNAs (Zeng et al, ) have been identified to be involved in the tumorgenesis of BC as oncogenes or tumor suppressors.…”

Section: Introductionmentioning

confidence: 99%

MiR‐142‐3p functions as a tumor suppressor by targeting RAC1/PAK1 pathway in breast cancer

Pan

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

MicroRNA -142-3p (miR-142-3p) was previously investigated in various cancers, whereas, itʼs role in breast cancer (BC) remains far from understood. In this study, we found that miR-142-3p was markedly decreased both in cell lines and BC tumor tissues. Elevated miR-142-3p expression suppressed growth and metastasis of BC cell lines via gain-of-function assay in vitro and in vivo. Mechanistically, miR-142-3p could regulate the ras-related C3 botulinum toxin substrate 1 (RAC1) expression in protein level, which simultaneously suppressed the epithelial-to-mesenchymal transition related protein levels and the activity of PAK1 phosphorylation, respectively. In addition, rescue experiments revealed RAC1 overexpression could reverse tumorsuppressive role of miR-142-3p. Our results showed miR-142-3p could function as a tumor suppressor via targeting RAC1/PAK1 pathway in BC, suggesting a potent therapeutic target for BC treatment. K E Y W O R D Sbreast cancer, miR-142-3p, PAK1, RAC1

show abstract

Section: Introductionmentioning

confidence: 99%

MiR‐142‐3p functions as a tumor suppressor by targeting RAC1/PAK1 pathway in breast cancer

Pan

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…Furthermore, many lncRNAs have important roles in various physiological and pathological processes . As to cancers, numerous lncRNAs have been shown to influence cell proliferation, cell cycle, cell apoptosis, cell senescence, cell migration and invasion, drug‐resistance, in vivo tumour growth and metastasis and so on . Therefore, several lncRNAs were identified to be potential therapeutic targets for various cancers .…”

Section: Introductionmentioning

confidence: 99%

Long non‐coding RNA LINC00526 represses glioma progression via forming a double negative feedback loop with AXL

Yan

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Glioma is the most common primary intracranial carcinoma with extremely poor prognosis. The significances of long non‐coding RNA (lncRNA) involved in glioma have been started revealed. However, the expression, roles and molecular mechanisms of most lncRNAs in glioma are still unknown. In this study, we identified a novel lncRNA LINC00526, which is significantly low expressed in glioma. Low expression of LINC00526 is correlated with aggravation and poor survival in glioma. Functional assays revealed that ectopic expression of LINC00526 inhibits glioma cell proliferation, migration, and invasion. LINC00526 silencing promotes glioma cell proliferation, migration and invasion. Mechanistically, we found that LINC00526 directly interacts with EZH2, represses the binding of EZH2 to AXL promoter, attenuates the transcriptional activating roles of EZH2 on AXL , and therefore represses AXL expression. Via repressing AXL, LINC00526 further represses PI3K/Akt/NF‐κB signalling. Intriguingly, we identified that NFKB1 and NFKB2 directly binds LINC00526 promoter and represses LINC00526 transcription. We further found that via activating NF‐κB signalling, AXL represses LINC00526 transcription. Therefore, LINC00526/EZH2/AXL/PI3K/Akt/NF‐κB form a feedback loop in glioma. Analysis of the TCGA data revealed that the expression of LINC00526 is inversely correlated with that of AXL in glioma tissues. In addition, functional rescue assays revealed that the tumour suppressive roles of LINC00526 are dependent on the negative regulation of AXL. Collectively, our data identified LINC00526 as a tumour suppressor in glioma via forming a double negative feedback loop with AXL. Our data also suggested LINC00526 as a potential prognostic biomarker and therapeutic candidate for glioma.

show abstract

“…LncRNA is a class of transcript with more than 200 nucleotides in length, but do not encode proteins . Aberrant expressions of lncRNAs have been revealed in various pathological status, particular in cancers . Furthermore, lncRNAs also play important roles in various pathophysiological processes, including cancers .…”

Section: Introductionmentioning

confidence: 99%

A positive feedback loop between ZNF205‐AS1 and EGR4 promotes non‐small cell lung cancer growth

Lin

Yang

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

Accumulating evidences revealed that long noncoding RNAs (lncRNAs) are frequently implicated in non‐small cell lung cancer (NSCLC). Herein, we reported the identification of a novel NSCLC‐associated functional lncRNA ZNF205 antisense RNA 1 (ZNF205‐AS1). ZNF205‐AS1 was increased in NSCLC tissues and cell lines, and associated with poor prognosis of NSCLC patients. Bioinformatics prediction, combined with experimental verification revealed that early growth response 4 (EGR4) directly bound to ZNF205‐AS1 promoter, increased the promoter activity of ZNF205‐AS1, and activated ZNF205‐AS1 transcription. Intriguingly, ZNF205‐AS1 transcript directly interacted with EGR4 mRNA, increased EGR4 mRNA stability, and up‐regulated EGR4 expression via RNA‐RNA interaction. Thus, ZNF205‐AS1 and EGR4 formed a positive feedback loop. Through regulating EGR4, ZNF205‐AS1 activated its own promoter activity. EGR4 was also increased in NSCLC and the expression of ZNF205‐AS1 was significantly positively correlated with EGR4 in NSCLC tissues. Gain‐of‐function and loss‐of‐function assays demonstrated that both ZNF205‐AS1 and EGR4 promoted NSCLC cell growth in vitro and NSCLC tumour growth in vivo. Concurrently depleting ZNF205‐AS1 and EGR4 more significantly repressed NSCLC tumour growth in vivo. Collectively, our study demonstrated that the positive feedback loop between ZNF205‐AS1 and EGR4 promotes NSCLC growth, and implied that targeting this feedback loop may be promising therapeutic strategy for NSCLC.

show abstract

lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer

Cited by 375 publications

References 70 publications

MiR‐142‐3p functions as a tumor suppressor by targeting RAC1/PAK1 pathway in breast cancer

MiR‐142‐3p functions as a tumor suppressor by targeting RAC1/PAK1 pathway in breast cancer

Long non‐coding RNA LINC00526 represses glioma progression via forming a double negative feedback loop with AXL

A positive feedback loop between ZNF205‐AS1 and EGR4 promotes non‐small cell lung cancer growth

Contact Info

Product

Resources

About